EP1455776A1 - Metabolite non arythmogene de l'oxybutynine - Google Patents

Metabolite non arythmogene de l'oxybutynine

Info

Publication number
EP1455776A1
EP1455776A1 EP01988410A EP01988410A EP1455776A1 EP 1455776 A1 EP1455776 A1 EP 1455776A1 EP 01988410 A EP01988410 A EP 01988410A EP 01988410 A EP01988410 A EP 01988410A EP 1455776 A1 EP1455776 A1 EP 1455776A1
Authority
EP
European Patent Office
Prior art keywords
ethylamino
pharmaceutically acceptable
oxybutynin
acceptable salt
butynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01988410A
Other languages
German (de)
English (en)
Other versions
EP1455776A4 (fr
Inventor
A. K Gunnar Aberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bridge Pharma Inc
Original Assignee
Bridge Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Pharma Inc filed Critical Bridge Pharma Inc
Priority claimed from PCT/US2001/050567 external-priority patent/WO2003066042A1/fr
Publication of EP1455776A1 publication Critical patent/EP1455776A1/fr
Publication of EP1455776A4 publication Critical patent/EP1455776A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate

Definitions

  • the invention relates to the racemic mono-desethyl metabolite of 4-diethylamino- 2-butynyl cyclohexylphenylglycolate.
  • the chemical name of this metabolite is 4- ethylamino-2-butynyl cyclohexylphenylglycolate and it is also called desethyloxybutynin (DEO).
  • the compound 4-diethylamino-2-butynyl cyclohexylphenylglycolate has the generic name oxybutynin (OXY) and is an approved drug for the management of urinary incontinence and pollakiuria.
  • DEO is now suggested to be used by individuals suffering from urinary incontinence or pollakiuria and also by patients suffering from gastrointestinal and other smooth muscle hypermotility disorders. DEO is particularly useful since this compound does not cause the cardiovascular side effects that are caused by OXY.
  • the compound oxybutynin (OXY) and has the following chemical structure:
  • Oxybutynin The compound desethyloxybutynin (DEO) and has the following chemical structure:
  • Racemic oxybutynin is used therapeutically in the treatment of urinary incontinence due to detrusor muscle instability.
  • the drug may also be used in patients suffering from gastrointestinal hypermotility disorders such as for example irritable bowel syndrome (IBS).
  • IBS irritable bowel syndrome
  • OXY exerts a spasmolytic effect by inhibiting the contractions of smooth muscles with cholinergic innervation.
  • OXY increases bladder capacity, diminishes the frequency of involuntary contractions of the detrusor muscle, and delays the initial desire to void. OXY is therefore useful in the treatment and prevention of both incontinence and frequent voluntary urination.
  • a secondary amine metabolite of OXY has been identified in humans after administration of OXY and is called desethyloxybutynin (DEO) (Douchamps et al. 1988).
  • a primary amine metabolite, didesethyl-oxybutynin (DIDEO) has now been synthesized.
  • DIDEO was found to be less potent than DEO as an antimuscarinic agent, but like DEO, DIDEO does not have the cardiac side effects of OXY and DIDEO may be useful as an antimuscarinic drug (Aberg et al. to be published.)
  • a third metabolite, called N-oxide- oxybutynin has been suggested but may not be chemically or metabolically stable (Lindeke et al., 1981).
  • Terodiline is another antimuscarinic dug for urinary incontinence and it was withdrawn from the market because it caused prolongation of the QTc interval of the ECG with concomitant and lethal Torsades de Pointes cardiac arrhythmias.
  • Torsades de Pointes is certainly the most unwanted side effect of oxybutynin, and it is of concern to all patients given oxybutynin.
  • patients who are of age (Hughes et al. 1992) or patients who have pre-existing cardiovascular conditions, such as for example long basal QTc interval, will therefore be at special risk for Torsades de Pointes arrhythmias. It is in this context of importance that most patients taking drugs for urinary incontinence are elderly individuals.
  • CYP 3A4 Since the metabolism of oxybutynin to desethyl-oxybutynin is utilizing an enzyme called CYP 3A4, patients who of hereditary reasons are "slow metabolizers" will accumulate high concentrations of oxybutynin and will therefore be at risk for developing drug-induced risk for Torsades de Pointes arrhythmias. It has also been described that certain types of drugs that utilize the same or similar metabolic enzymes as oxybutynin, will further increase the risk for Torsades de Pointes when combined with oxybutynin. Examples of such drugs are ketoconazole and erythromycin.
  • the present invention relates to a method for treating and/or preventing urinary incontinence and pollakiuria while reducing concomitant liability of adverse effects associated with oxybutynin, which comprises administering to a human in need of such treatment a therapeutically effective amount of 4-ethylamino-2-butynyl cyclohexyl-phenylglycolate or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a method for treating and/or preventing urinary incontinence and pollakiuria while reducing concomitant liability of cardiac side effects associated with oxybutynin, which comprises administering to a human in need of such treatment a therapeutically effective amount of 4-ethylamino-2-butynyl cyclohexyl-phenylglycolate or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a method for treating urinary incontinence and pollakiuria while reducing concomitant liability of cardiac arrhythmogenic side effects associated with oxybutynin, which comprises administering to a human in need of such treatment a therapeutically effective amount of 4-ethylamino-2-butynyl cyclohexyl-phenylglycolate or a pharmaceutically acceptable salt thereof
  • Oxybutynin is 4-diethylamino-2-butynyl ⁇ -cyclohexyl- ⁇ -hydroxybenzeneacetate, also known as 4-diethylamino-2-butynyl cyclohexylphenylglycolate and herein referred to as OXY.
  • the generic name given to the hydrochloride salt of oxybutynin by the USAN Council is oxybutynin chloride; it is sold under various names, such as for example Ditropan ® and Ditropan XL ®
  • Desethyloxybutynin is 4-ethylamino-2-butynyl cyclohexylphenyl-glycolate and is a known metabolite of oxybutynin (Hughes et al. 1992). This compound is herein referred to as DEO. No generic name is known for this compound or any of its salts.
  • the overall process for preparing DEO involves:
  • An alternative process for preparing the compound of the invention involves the preparation of a hydroxylated side chain in stead of the above mentioned halogenated side chain.
  • Cyclohexylphenylglycolic acid is commercially available from SIPSY Chem Corp., 2137 Route 33, Suite 2, Hamilton Square, NJ 08690.
  • a prophylactic or therapeutic dose of the compound of this invention in the acute or chronic management of disease will vary with the severity and nature of the condition to be treated and the route of administration.
  • the dose and the frequency of the dosing will also vary according to the age, body weight and response of the individual patient.
  • the total daily dose range for the compound of this invention for the conditions described herein is from about 1 mg to about 100 mg in single or divided doses, preferably in divided doses.
  • the therapy should be initiated at a lower dose, perhaps at about 0.5 mg to about 25 mg, and may be increased up to about 200 mg depending on the patient's global response.
  • Any suitable route of administration may be employed for providing the patient with an effective dosage of the compound of this invention.
  • oral, sublingual, rectal, parental (subcutaneous, intramuscular, intravenous), intraocular, transdermal, aerosol and like forms of administration may be employed.
  • Dosage forms include tablets, controlled-release tablets, troches, dispersions, suspensions, solutions, capsules, microencapsulated systems, sprays, transdermal delivery systems, and the like.
  • compositions of the present invention comprise the compound of the present invention as the active ingredient, or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier, and optionally, other therapeutic ingredients.
  • Suitable pharmaceutically acceptable acid addition salts for the compound of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pathothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, and the like.
  • compositions of the present invention include suspensions, solutions, elixirs or solid dosage forms.
  • Carriers such as starches, sugars, and microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like are suitable in the case of oral solid preparations (such as powders, capsules, and tablets), and oral solid preparations are preferred over the oral liquid preparations.
  • tablets and capsules represent one of the more advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Since the compound of the invention has a relatively short duration of action in the body, it may be advantageous to administer the drug in a controlled-released or slow-release formulation, thereby decreasing the frequency of drug administrations to the patient as well as reducing the side effects, including the anticholinergic side effects, of the drug. The compounds of the present invention may also be administered by controlled release means and delivery devices such as those described in U.S.
  • Various forms of controlled release or slow release transdermal administration forms and devices can also be used to improve the convenience of dosage for the patient and are hereby incorporated by reference.
  • compositions of the present invention suitable for oral administration may be presented as discrete unit dosage forms such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation, just as is known for the racemic mixture.
  • a tablet may be prepared by compression or molding, optionally, with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active agent or dispersing agent.
  • Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. All of the foregoing techniques are well know to persons of skill in the pharmaceutical art.
  • Each tablet may contain from about 0.5 mg to about 25 mg of the active ingredient.
  • the compound of the present invention is blended with the lactose and cellulose until a uniform blend is formed.
  • the lake is added and further blended.
  • the calcium stearate is blended in, and the resulting mixture is compressed into tablets using a 9/32 inch (7 mm) shallow concave punch. Tablets of other strengths may be prepared by altering the ration of active ingredient to the excipients or to the final weight of the tablet.
  • the surprising utility of the compound of the present invention has been established by the following studies.
  • the experiments are carried out on membranes prepared from SF9 cells infected with baculo virus to express human recombinant muscarinic receptor subtypes. After incubation with the test article and the proper radioligand and washing, bound radioactivity is determined with a liquid scintillation counter, using a commercial scintillation cocktail.
  • the specific radioligand binding to each receptor is defined as the difference between total binding and nonspecific binding determined in the presence of an excess of unlabelled ligand. IC 50 values (concentrations required to inhibit 50% of specific binding) were determined by non linear regression analysis of the competition curves.
  • OXY oxybutynin
  • DEO desethyl-oxybutynin
  • contractions of each strip of tissue are recorded initially in response to exposure to a tissue medium in which the NaCl was replaced by KCl to yield a concentration of 137.7 mM KCl in the medium. This is followed by return to the standard medium, and then by exposures to progressively creasing concentrations of carbachol, with separate exposures to each concentration only until the peak response has been recorded. Then, leaving one strip untreated and/or one strip exposed to the test solution to serve as control tissue(s), the remaining strips each are exposed for one hour to one concentration of an antagonist. Finally, the responses to increasing concentrations of carbachol followed by exposure to 137.7 mM KCl are recorded a second time.
  • the peak tension developed by each strip during the second set of determinations is expressed as a percent of the peak tension developed during the first concentration-effect determination. Then, for each antagonist the resultant data are analyzed using standard statistical methodology.
  • pA 2 the negative logarithm of the concentration of an antagonist that doubles EC 50 of an agonist.
  • guinea pigs Male guinea pigs (450-600 g) are anesthetized with freshly prepared dialurethane sodium. The jugular vein is catheterized for iv administration of test drugs and the trachea is exposed and cannulated. Subdermal electrodes are positioned for Lead II electrocardiogram recording, monitored on a Grass Polygraph recorder, set at a paper speed of 50 mm/sec. The animals are allowed to stabilize for 30 minute after completion of surgery, and three baseline EKG recordings are then made at 10-minute intervals. The animals are then given 5 mg/kg of a test compound or vehicle as an intravenous infusion over 30 min. EKG recordings are used to determine QT intervals and heart rates.
  • QTc intervals are calculated from QT- and RR- intervals as known to those skilled in the art (Bazett's formula). Prolongation of QTc is indicative of a prolonged action potential, caused by an inhibition of the delayed rectifier potassium channel. Prolongation of QTc is the known cause of Torsades de Pointes ventricular fibrillation by drugs such as terfenadine, astemizole and terodiline (now withdrawn from the market). Results:
  • Such equivalents also include the simultaneous administration of the compound of the present invention with any other drug that is used to combat diseases in mammals, mentioned in this document.
  • Such equivalents also include the co-administration of the compound of the present invention with any other compound or drug that may be used in combination with medication for urinary incontinence or intestinal hyperactivity or other forms of smooth muscle, such as for example renal, biliary and respiratory/bronchial hyperactivity or hyperreactivity.
  • medication for urinary incontinence or intestinal hyperactivity or other forms of smooth muscle such as for example renal, biliary and respiratory/bronchial hyperactivity or hyperreactivity.
  • the didesethyl metabolite of oxybutynin has pharmacological activities that are similar to those of des-ethyl oxybutynin, although the didesethyl metabolite has somewhat lower affinity for muscarinic receptors than the des-ethyl metabolite. Since the didesethyl metabolite does not prolong the QTc interval of the ECG, this metabolite and its optically active isomers and the salt forms thereof are of therapeutic use and are intended to be included into the present invention.
  • the compound desethyl-oxybutynin is an antimuscarinic drug that is useful also for other therapeutic indications than urinary incontinence, pollakiuria and intestinal hyperactivity.
  • desethyl-oxybutynin may decrease the contractile activity of other smooth muscles with muscarinic (cholinergic) innervation, as for example biliary smooth muscle, renal smooth muscle and respiratory/ bronchial smooth muscle.
  • the drug can also effectively inhibit muscarinic innervation to various glands, such as for example sweat glands and may therefore be used for the treatment of excessive sweat production.
  • Desethyl-oxybutynin can also be used for treatment of acute pancreatitis.
  • Des-ethyl oxybutynin may be particularly useful for these therapeutic indications since desethyloxybutynin does not carry the risk for prolonged QTc and Torsades de Pointes cardiac arrhythmias. These therapeutic indications for desethyl-oxybutynin are also included in the present invention
  • intestinal hyperactivity disorders and intestinal hypermotility disorders include irritable bowel syndromes (IBS).
  • IBS irritable bowel syndromes
  • the compounds of the invention having certain pharmacological properties (such as antimuscarinic activity on various receptor types, calcium antagonistic activity, spasmolytic activity on various types of smooth muscle etc.), while not causing cardiac side effects, such as for example Torsades de Pointes arrhythmias, may be useful for other indications than those listed here. Such indications are equivalents to the specific embodiments of the invention described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne le traitement et la prévention de l'incontinence urinaire et de la pollakiurie avec la possibilité d'atténuer les risques de survenue des effets indésirables associés à l'oxybutine. A cet effet, on administre au patient justifiant d'un tel traitement une quantité suffisante de 4-éthylamino-2-butynyle cyclohexyl-phényglycolate ou de l'un de ses sels pharmaceutiquement admis.
EP01988410A 2001-12-21 2001-12-21 Metabolite non arythmogene de l'oxybutynine Withdrawn EP1455776A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/050567 WO2003066042A1 (fr) 2000-02-03 2001-12-21 Metabolite non arythmogene de l'oxybutynine

Publications (2)

Publication Number Publication Date
EP1455776A1 true EP1455776A1 (fr) 2004-09-15
EP1455776A4 EP1455776A4 (fr) 2006-05-17

Family

ID=32823140

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01988410A Withdrawn EP1455776A4 (fr) 2001-12-21 2001-12-21 Metabolite non arythmogene de l'oxybutynine

Country Status (3)

Country Link
EP (1) EP1455776A4 (fr)
JP (1) JP2005516992A (fr)
AU (1) AU2002241721A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
WO2001093683A1 (fr) * 2000-06-07 2001-12-13 Watson Pharmaceuticals, Inc. Traitement de l'hyperactivite de muscles lisses avec (r)-oxybutynine et (r)-desethyloxybutynine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
WO2001093683A1 (fr) * 2000-06-07 2001-12-13 Watson Pharmaceuticals, Inc. Traitement de l'hyperactivite de muscles lisses avec (r)-oxybutynine et (r)-desethyloxybutynine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO03066042A1 *
SMITH E R ET AL: "Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline." ARZNEIMITTEL-FORSCHUNG. OCT 1998, vol. 48, no. 10, October 1998 (1998-10), pages 1012-1018, XP008061986 ISSN: 0004-4172 *

Also Published As

Publication number Publication date
JP2005516992A (ja) 2005-06-09
EP1455776A4 (fr) 2006-05-17
AU2002241721A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
US6310103B1 (en) S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0806948B1 (fr) Traitement de l'incontinence urinaire par la (s)-oxybutynine et la (s)-desethyloxybutynine
US6123961A (en) Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
CA2257121C (fr) Methodes et compositions pour le traitement de l'incontinence urinaire utilisant (s)-oxybutynine
US5532278A (en) Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
AU2000255966B2 (en) Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin
US6432446B2 (en) Non-arrhythmogenic metabolite of oxybutynin
US6974820B2 (en) Methods for treating urinary incontinence and other disorders using trospium
US20030027856A1 (en) Tolterodine metabolites
EP1455776A1 (fr) Metabolite non arythmogene de l'oxybutynine
JP2012176958A (ja) （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
JP2005516992A6 (ja) オキシブチニンの非心律動異常惹起性代謝物
WO1998001125A2 (fr) Isomeres dextrogyres d'oxybutynine et de desethyloxybutynine utilises dans le traitement de l'hyperactivite gastro-intestinale
CA2503746A1 (fr) Methodes de traitement de l'incontinence urinaire et d'autres troubles a l'aide de trospium
MXPA97005820A (en) The use of (s) -oxibutinin and (s) -desetiloxibutinin in the preparation of compositions for the treatment of urinary incontinence, the compositions obtained and the procedure for preparing desetiloxibitin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040617

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060331

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/216 20060101AFI20060327BHEP

17Q First examination report despatched

Effective date: 20060922

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070203